Refine
Has Fulltext
- yes (112)
Is part of the Bibliography
- yes (112)
Year of publication
Document Type
- Journal article (112) (remove)
Language
- English (112) (remove)
Keywords
- tissue engineering (10)
- regenerative medicine (6)
- stem cells (6)
- 3D tissue model (4)
- gene expression (4)
- in vitro (4)
- inflammation (4)
- Bordetella pertussis (3)
- chondrocytes (3)
- collagens (3)
- electrospinning (3)
- extracellular matrix (3)
- B cells (2)
- BMP (2)
- BMP-2 (2)
- Bone morphogenetic protein-2 (2)
- Hirschsprung disease (2)
- Neisseria gonorrhoeae (2)
- SARS-CoV-2 (2)
- anthocyanins (2)
- bioengineering (2)
- biological models (2)
- bioreactor (2)
- blood-brain barrier (BBB) model (2)
- bone regeneration (2)
- co-culture (2)
- decellularization (2)
- discriminant analysis (2)
- extracellular vesicles (2)
- growth factor beta (2)
- impedance spectroscopy (2)
- infection (2)
- invasion (2)
- mesenchymal stem cells (2)
- migration (2)
- multiple myeloma (2)
- osteoarthritis (2)
- permeability (2)
- phenotype (2)
- principal component analysis (2)
- raman spectroscopy (2)
- rat (2)
- reconstructed human epidermis (2)
- scaffolds (2)
- subcutaneous animal model (2)
- therapy (2)
- vascularization (2)
- 1st-line treatment (1)
- 3D in vitro models (1)
- 3D lung tumor model (1)
- 3D lung tumor tissue models (1)
- 3D models (1)
- 3D scaffolds (1)
- 3D tissue models (1)
- 5-Fluorouracil (1)
- ATMP (1)
- Adenylate cyclase toxin (1)
- Aggregatibacter actinomycetemcomitans (1)
- Alternative test methods (1)
- Alzheimer′s disease (1)
- Apoptosis (1)
- Articular-Cartilage (1)
- Assay (1)
- B cell receptors (1)
- BMP-2 delivery (1)
- BRAF mutation (1)
- Beta-catenin (1)
- BioVaSc (1)
- Biocompatibility (1)
- Biodegradable polymer scaffolds (1)
- Biomechanical Properties (1)
- Biomedical engineering (1)
- Bone tissue engineering (1)
- Boolean signaling network (1)
- CCR2 (1)
- CCR4 (1)
- CNS disease (1)
- CYP induction (1)
- CYP inhibition (1)
- CYR61 (1)
- Caco2 cells (1)
- Cancer (1)
- Carcinoma cells (1)
- Cardiac ventricles (1)
- Cell replacement therapy (1)
- Chemicals (1)
- Collagen (1)
- Compressive Properties (1)
- Data acquisition (1)
- Diffusion tensor imaging (1)
- Draize eye test (1)
- ECM coating (1)
- EMT (1)
- EVs (1)
- Eigenvectors (1)
- Enteric nervous system (1)
- Enteric neuropathies (1)
- Episkin (1)
- Eriodictyon californicum (1)
- FTIR spectroscopy (1)
- Fibroblasts (1)
- Fluorouracil (1)
- GDF-5 (1)
- GLUTs (1)
- GMP (1)
- GUT (1)
- Gene regulation (1)
- Glucose transport (1)
- Growth; BMP-2 (1)
- HSP90 inhibitor (1)
- HUVEC (1)
- Head and neck cancers (1)
- Heart (1)
- Hirschsprung disease liability (1)
- Human Knee (1)
- Human Medial Meniscus (1)
- Hypertrophic pyloric-stenosis (1)
- IL-1ß (1)
- IL-6 (1)
- In vitro skin irritation testing (1)
- In-vitro (1)
- In-vivo (1)
- Injuries (1)
- Intestinal pseudoobstruction (1)
- Invasion (1)
- Irritable bowel syndrome (1)
- KRAS biomarker signatures (1)
- KRAS mutation signature (1)
- LCST (1)
- MSC (1)
- Magnetic resonance imaging (1)
- Mandibular continuity defects (1)
- Marrow stromal cells (1)
- Matrix (1)
- Mechanisms (1)
- Medicine (1)
- Mesenchymal transition (1)
- Microenvironment (1)
- Model (1)
- Models (1)
- Multicenter randomized-trial (1)
- Myofibroblast differentiation (1)
- NK cells (1)
- NOTCH (1)
- NRAS mutation (1)
- Neisseria meningitidis (1)
- Neural crest cells (1)
- Nitric-oxide (1)
- OECD guideline (1)
- OLFM4 (1)
- Open source reconstructed epidermis (1)
- Oral squamous cell carcinoma (1)
- Osteoarthritis (1)
- Oxide synthase gene (1)
- Pancreatic islet (1)
- Proliferation (1)
- R57A (1)
- RHE (1)
- Rat mynteric plexus (1)
- Receptor (1)
- Repair (1)
- SGLTs (1)
- Salmonella (1)
- Salmonella Typhimurium (1)
- Sinus floor augmentation (1)
- Slow-transit constipation (1)
- Smooth-muscle-cells (1)
- Squamous-cell carcinoma (1)
- Stem cells (1)
- Stem-cell biotechnology (1)
- Streptococcus oralis (1)
- Swine (1)
- TEER (1)
- TGF-beta (1)
- TGFβ/BMP signaling (1)
- Term follow-up (1)
- Tissue (1)
- Tractography (1)
- Triple co-culture (1)
- Tumorigenicity (1)
- Validation (1)
- Vivo (1)
- acetylsalicylic acid (1)
- acid dissociation (1)
- adenocarcinoma of the lung (1)
- adenylate cyclase toxin (1)
- adhesion (1)
- adults (1)
- aging (1)
- air-liquid interface (1)
- airway epithelia (1)
- albumins (1)
- algorithm (1)
- alternative to animal testing (1)
- alternatives (1)
- anaesthetics (1)
- anatomy (1)
- animal model (1)
- antagonist (1)
- antennas (1)
- anthocyanin (1)
- antibiotics (1)
- antioxidative (1)
- antitumor peptide (1)
- antiviral activity (1)
- apoptosis (1)
- artificial membrane-permeability (1)
- aspirin (1)
- astaxanthin (1)
- asthmatic bronchial epithelium (1)
- astrocytes (1)
- autologous (1)
- autologous chondrocyte implantation (1)
- automation (1)
- automation & robotics (1)
- bacteria (1)
- bacterial cellulose dressing (1)
- bacterial migration (1)
- bacterial virulence (1)
- barrier models (1)
- benzalkonium chloride (1)
- beta-aminopropionitrile (1)
- beta-cyclodextrin (1)
- betaglycan (1)
- bilberry (1)
- biocompatibility (1)
- biocompatible materials (1)
- bioconjugation (1)
- biofilm (1)
- bioinformatics (1)
- biological barriers (1)
- biological scaffold (1)
- biology (1)
- biomaterial tests (1)
- biomedical engineering (1)
- biomedical materials (1)
- biomimetic 3D tissue model (1)
- bioreactor culture (1)
- biotechnology (1)
- black currant (1)
- blood (1)
- blood pressure (1)
- blood-brain barrier (1)
- blood-cerebrospinal fluid barrier (1)
- blood‐brain barrier (BBB) (1)
- bone critical size defect (1)
- bone marrow (1)
- bone morphogenetic protein (1)
- bone morphogenetic protein 2 (BMP2) (1)
- bone morphogenetic protein 9 (BMP9) (1)
- bone morphogenetic proteins (1)
- bone tissue engineering (1)
- boolean in silico models (1)
- brachtydacyly type A2 (1)
- brain endothelial cells (1)
- brain–liver chip (1)
- breast cancer cells (1)
- burn wound (1)
- calcium fluoride nanoparticles (1)
- cancer dissemination (1)
- cancer treatment (1)
- cancers and neoplasms (1)
- carbon fiber (1)
- cardiac device therapy (1)
- cardiac patch (1)
- cardiovascular (1)
- cardiovascular MR methods (1)
- cartilage (1)
- cartilage defectex vivo model (1)
- cartilage regeneration (1)
- cartilage repair (1)
- cartilage test system (1)
- cell binding (1)
- cell culture (1)
- cell cultures (1)
- cell cycle and cell division (1)
- cell differentiation (1)
- cell engineering (1)
- cell membrane model (1)
- cell metabolism (1)
- cell migration (1)
- cell proliferation (1)
- cellular biology (1)
- cellular microenvironment (1)
- cellular signalling networks (1)
- central nervous system (1)
- ceramide (1)
- chemokine receptor (1)
- chemoresistance (1)
- chiral resolution (1)
- chondrogenesis (1)
- chondrogenic differentiation (1)
- chondrogenic hypertrophy (1)
- ciliary neurotrophic factor (1)
- ciliostasis (1)
- circular dichroism (1)
- clinical applications (1)
- collagen sponge (1)
- collagen type I hydrogel (1)
- colon (1)
- colony-stimulating factor (1)
- colorectal cancer (1)
- combination of physical vapor deposition and electrochemical etching (1)
- combinatorial drug predictions (1)
- complexation (1)
- computer modelling (1)
- confocal Raman imaging (1)
- core depression (1)
- coreceptor (1)
- corneal endothelium (1)
- corneal epithelium (1)
- corneal equivalent (1)
- corneal storage (1)
- covalent coupling (1)
- critical size defect (1)
- cross-talk (1)
- cryostructured scaffolds (1)
- crystal structure (1)
- crystal-structure (1)
- culture techniques (1)
- cultured (1)
- cyclic adenosine monophosphate (1)
- cycloaddition (1)
- cyclodextrin (1)
- cytokine (1)
- cytokines (1)
- cytotoxicity (1)
- defects (1)
- defined humanized test system (1)
- dendritic cell (1)
- dental implants (1)
- diabetes (1)
- differentiation (1)
- diffusion tensor imaging (1)
- dominant-negative mutatio (1)
- drug (1)
- drug metabolism (1)
- drug permeability screening (1)
- drug resistance (1)
- dry spinning (1)
- dynamic culture (1)
- dynamic culture conditions (1)
- dystrophic RCS rats (1)
- early diagnosis (1)
- elastic fibers (1)
- elastin (1)
- electrical and electronic engineering (1)
- embryonic stem cell (1)
- embryonic stem cells (1)
- endothelial cells (1)
- endothelial growth factor (1)
- enteric nervous system (1)
- enzyme metabolism (1)
- epidermis (1)
- epithelial cell culture (1)
- epithelial cells (1)
- equipment and supplies (1)
- establishment (1)
- ex vivo model (1)
- experimental models of disease (1)
- expression (1)
- eye irritation testing (1)
- factor binding profiles (1)
- factor-VIII (1)
- fibroblast chemotaxis (1)
- fibroblast growth factor (1)
- fibrosis (1)
- filamentous Salmonella Typhimurium (1)
- fixation (1)
- flavonoids (1)
- follistatin 288 (FST288) (1)
- follistatin 315 (FST315) (1)
- foreign body reaction (1)
- formalin (1)
- full thickness skin (1)
- functional initiators (1)
- gamma-cyclodextrin (1)
- gastrointestinal tract (1)
- gels (1)
- gene encoding noggin (1)
- gene therapy (1)
- genetic engineering (1)
- glucose transporter SGLT1 (1)
- glycoprotein (1)
- growth and differentiation factor 5 (1)
- hBMSC (1)
- head and neck squamous cell carcinoma (1)
- heart structure (1)
- heart valve (1)
- heparin binding sites (1)
- heptaocytes (1)
- herpesvirus (1)
- highly porous materials (1)
- host (1)
- host modulation (1)
- human (1)
- human airway mucosa tissue models (1)
- human bruchs membrane (1)
- human exposure (1)
- human heptocytes (1)
- human induced pluripotent stem cells (hiPSCs) (1)
- human induced pluripotent stem cells (hiPSCs)human induced pluripotent stem cells (hiPSCs) (1)
- human liver cells (1)
- human nasal epithelial cells (1)
- human osteosarcoma xenografts (1)
- human respiratory epithelial cells (1)
- human tracheo-bronchial epithelial cells (1)
- human‐induced pluripotent stem cells (hiPSC) (1)
- hybrid pacemaker (1)
- hyperlipidemia (1)
- hypoxia inducible factor 1 (1)
- immune cell infiltration (1)
- immunotherapeutics (1)
- immunotherapies (1)
- immunotherapy (1)
- in silico simulation (1)
- in situ guided tissue regeneration (1)
- in vitro models (1)
- in vivo (1)
- in vivo experiments (1)
- in-vitro (1)
- in-vitro models (1)
- induction (1)
- infectious disease (1)
- inflammation-induced tissue demage (1)
- inflammatory bowel disease (1)
- inflammatory response (1)
- injectable in situ gelling slow release system (1)
- insilico drug screening too (1)
- interface (1)
- intestinal enteroids (1)
- invasiveness (1)
- inflammatory response (1)
- iron metabolism (1)
- irradiation (1)
- kinetics (1)
- label-free analysis (1)
- laser microdissection (1)
- ligand binding (1)
- ligand-receptor complex (1)
- ligand-receptor promiscuity (1)
- lipids (1)
- liposome (1)
- living cells (1)
- lncRNAs (1)
- long-term (1)
- lower critical solution temperature (1)
- lung and intrathoracic tumors (1)
- lung cancer (1)
- magnetic resonance imaging (MRI) (1)
- malignant tumors (1)
- manufacturing (1)
- measels virus (1)
- measles virus (1)
- mechanisms of disease (1)
- medicine (1)
- melanoma metastases (1)
- membrane receptor signaling (1)
- memory (1)
- meningococcus (1)
- mesenchymal cells (1)
- mesenchymal stromal cell (1)
- mesenchymal tissues (1)
- mesothelium (1)
- metabolic flux analysis (1)
- metallo-supramolecular polymer (1)
- miRNAs (1)
- microbe carrier (1)
- microenvironment (1)
- microparticles (1)
- microphysiological systems (MPS) (1)
- microplastics (1)
- microvascular endothelial cells (1)
- microwave radiation (1)
- midazolam (1)
- modular tumor tissue models (1)
- moisture balance (1)
- molecular biology (1)
- molecular diagnostics (1)
- molecular mechanism (1)
- morphogenetic protein receptors (1)
- motility disorders (1)
- multi-organ chip (1)
- multicellular tumor spheroids (1)
- multifunctional nanoparticles (1)
- multilayered skin (1)
- multimodal imaging (1)
- multipotent fetal neural stem cells (fNSCs) (1)
- multivariate data analysis (1)
- murine (1)
- mutagenesis (1)
- myenteric plexus (1)
- nanoparticles (1)
- nanoplastics (1)
- nanotopographical surfaces (1)
- necrosis-factor-alpha (1)
- necrotic cell death (1)
- neural stem-cell (1)
- neurology (1)
- neuronal electrodes (1)
- neurotoxicity (1)
- neurovascular unit in vitro (1)
- neutrophil transmigration (1)
- non-invasive biomarkers (1)
- occupancy (1)
- olfactomedin 4 (1)
- on-a-chip (1)
- open-access database (1)
- open-source epidermis (1)
- oragnoids (1)
- organ-on-a-chip (1)
- organotypic (1)
- organotypic oral mucosa (1)
- osteoblasts (1)
- osteochondral allografts (1)
- osteochondral biopsy (1)
- osteochondral lesion (1)
- osteogenesis (1)
- osteogenesis imperfecta (1)
- osteogenic differentiation (1)
- osteoporosis (1)
- outgrowth endothelial cells (1)
- ovarian cancer (1)
- oxidative DNA damage (1)
- pancreatic cancer (1)
- pancreatic islet cytomorphology (1)
- pancreatic islet function (1)
- parasitology (1)
- perfusion-based bioreactor system (1)
- peritoneal metastasis (1)
- pharmaceutical applications (1)
- phosphatidylserine (1)
- photoluminescence (1)
- physiology (1)
- platelet-derived growth factor (1)
- pluripotent stem cells (1)
- polymer (1)
- polymerization (1)
- polymers (1)
- polypeptoids (1)
- postpolymerization modification (1)
- precision-cut lung slices (1)
- preclinical drug discovery (1)
- primary cell isolation (1)
- primary cells (1)
- primary human hepatocytes (1)
- progenitor cells (1)
- progenitors (1)
- proteins (1)
- pulmonary drug-delivery (1)
- pulmonary imaging (1)
- pulses (1)
- quanititative characterization (1)
- quantification (1)
- randomized clinical trial (1)
- reactive oxygen species (1)
- real time PCR (1)
- receptor type III (1)
- reflection (1)
- relaxometry (1)
- repair (1)
- replacement (1)
- respiratory syncytial virus (1)
- responses (1)
- retinal pigment epithelium (1)
- rhBMP–2 (1)
- ring-opening polymerization (1)
- salicylic acid (1)
- salivary gland neoplasia (1)
- salivary gland tumor (1)
- salivary gland tumors (1)
- salivary glands (1)
- scaffold (1)
- scanning electron microscopy (1)
- secondary lung tumors (1)
- secondary wound dressing (1)
- segmental collapse (1)
- sevoflurane (1)
- sheep model (1)
- signal integration (1)
- signal specification (1)
- signal tranduction (1)
- signal transduction (1)
- signaling (1)
- signaling pathways (1)
- skin anatomy (1)
- skin equivalents (1)
- skin models (1)
- skin physiology (1)
- small intestinal submucosa scaffold (1)
- sodium channels (1)
- sol-gel chemistry (1)
- solid tumors (1)
- solubility (1)
- sphingosine-1-phosphate (1)
- starch (1)
- stemness (1)
- sterubin (1)
- stimulation (1)
- stratification (1)
- stromal cells (1)
- stromal tissues (1)
- subfoveal choroidal neovascularization (1)
- subretinal space (1)
- superfamily (1)
- supermolecular carrier systems (1)
- surgical oncology (1)
- systemic inflammatory response syndrome (1)
- targeted combination therapy (1)
- targeted therapy (1)
- technology (1)
- tight junction (1)
- tissue culture (1)
- tissue model (1)
- tissue preparation (1)
- tissue remodeling (1)
- toxicity (1)
- toxicology (1)
- trachea (1)
- tracheal cytotoxin (1)
- trafficking (1)
- transcapillary pressure gradient (1)
- transcriptomics (1)
- transforming growth factor-beta 1 (1)
- translational research (1)
- translocation (1)
- transplantation (1)
- transport studies (1)
- tumor cells (1)
- tumor model systems (1)
- tumor test system (1)
- upcyte hepatocytes (1)
- vascular normalization (1)
- vascular progenitor (1)
- vascular surgery (1)
- vascularized scaffold (1)
- vesicle-based barrier (1)
- viral epidemiology (1)
- viral infection (1)
- virulence (1)
- weight-bearing (1)
- wound healing (1)
- wound model (1)
- wound physiology (1)
- xenotransplantation (1)
- zinc oxide nanoparticles (1)
- α-Cell (1)
- α-cell (1)
- β-Cell (1)
- β-cell (1)
Institute
- Lehrstuhl für Tissue Engineering und Regenerative Medizin (112) (remove)
Sonstige beteiligte Institutionen
The impact of oral commensal and pathogenic bacteria on peri-implant mucosa is not well understood, despite the high prevalence of peri-implant infections. Hence, we investigated responses of the peri-implant mucosa to Streptococcus oralis or Aggregatibacter actinomycetemcomitans biofilms using a novel in vitro peri-implant mucosa-biofilm model. Our 3D model combined three components, organotypic oral mucosa, implant material, and oral biofilm, with structural assembly close to native situation. S. oralis induced a protective stress response in the peri-implant mucosa through upregulation of heat shock protein (HSP70) genes. Attenuated inflammatory response was indicated by reduced cytokine levels of interleukin-6 (IL-6), interleukin-8 (CXCL8), and monocyte chemoattractant protein-1 (CCL2). The inflammatory balance was preserved through increased levels of tumor necrosis factor-alpha (TNF-α). A. actinomycetemcomitans induced downregulation of genes important for cell survival and host inflammatory response. The reduced cytokine levels of chemokine ligand 1 (CXCL1), CXCL8, and CCL2 also indicated a diminished inflammatory response. The induced immune balance by S. oralis may support oral health, whereas the reduced inflammatory response to A. actinomycetemcomitans may provide colonisation advantage and facilitate later tissue invasion. The comprehensive characterisation of peri-implant mucosa-biofilm interactions using our 3D model can provide new knowledge to improve strategies for prevention and therapy of peri-implant disease.
Objectives
Glycemic control by medical treatment represents one therapeutic strategy for diabetic patients. The Na+-d-glucose cotransporter 1 (SGLT1) is currently of high interest in this context. SGLT1 is known to mediate glucose absorption and incretin secretion in the small intestine. Recently, inhibition of SGLT1 function was shown to improve postprandial hyperglycemia. In view of the lately demonstrated SGLT1 expression in pancreatic islets, we investigated if loss of SGLT1 affects islet morphology and function.
Methods
Effects associated with the loss of SGLT1 on pancreatic islet (cyto) morphology and function were investigated by analyzing islets of a SGLT1 knockout mouse model, that were fed a glucose-deficient, fat-enriched diet (SGLT1−/−-GDFE) to circumvent the glucose-galactose malabsorption syndrome. To distinguish diet- and Sglt1−/−-dependent effects, wildtype mice on either standard chow (WT-SC) or the glucose-free, fat-enriched diet (WT-GDFE) were used as controls. Feeding a glucose-deficient, fat-enriched diet further required the analysis of intestinal SGLT1 expression and function under diet-conditions.
Results
Consistent with literature, our data provide evidence that small intestinal SGLT1 mRNA expression and function is regulated by nutrition. In contrast, pancreatic SGLT1 mRNA levels were not affected by the applied diet, suggesting different regulatory mechanisms for SGLT1 in diverse tissues. Morphological changes such as increased islet sizes and cell numbers associated with changes in proliferation and apoptosis and alterations of the β- and α-cell population are specifically observed for pancreatic islets of SGLT1−/−-GDFE mice. Glucose stimulation revealed no insulin response in SGLT1−/−-GDFE mice while WT-GDFE mice displayed only a minor increase of blood insulin. Irregular glucagon responses were observed for both, SGLT1−/−-GDFE and WT-GDFE mice. Further, both animal groups showed a sustained release of GLP-1 compared to WT-SC controls.
Conclusion
Loss or impairment of SGLT1 results in abnormal pancreatic islet (cyto)morphology and disturbed islet function regarding the insulin or glucagon release capacity from β- or α-cells, respectively. Consequently, our findings propose a new, additional role for SGLT1 maintaining proper islet structure and function.
Patient-tailored therapy based on tumor drivers is promising for lung cancer treatment. For this, we combined in vitro tissue models with in silico analyses. Using individual cell lines with specific mutations, we demonstrate a generic and rapid stratification pipeline for targeted tumor therapy. We improve in vitro models of tissue conditions by a biological matrix-based three-dimensional (3D) tissue culture that allows in vitro drug testing: It correctly shows a strong drug response upon gefitinib (Gef) treatment in a cell line harboring an EGFR-activating mutation (HCC827), but no clear drug response upon treatment with the HSP90 inhibitor 17AAG in two cell lines with KRAS mutations (H441, A549). In contrast, 2D testing implies wrongly KRAS as a biomarker for HSP90 inhibitor treatment, although this fails in clinical studies. Signaling analysis by phospho-arrays showed similar effects of EGFR inhibition by Gef in HCC827 cells, under both 2D and 3D conditions. Western blot analysis confirmed that for 3D conditions, HSP90 inhibitor treatment implies different p53 regulation and decreased MET inhibition in HCC827 and H441 cells. Using in vitro data (western, phospho-kinase array, proliferation, and apoptosis), we generated cell line-specific in silico topologies and condition-specific (2D, 3D) simulations of signaling correctly mirroring in vitro treatment responses. Networks predict drug targets considering key interactions and individual cell line mutations using the Human Protein Reference Database and the COSMIC database. A signature of potential biomarkers and matching drugs improve stratification and treatment in KRAS-mutated tumors. In silico screening and dynamic simulation of drug actions resulted in individual therapeutic suggestions, that is, targeting HIF1A in H441 and LKB1 in A549 cells. In conclusion, our in vitro tumor tissue model combined with an in silico tool improves drug effect prediction and patient stratification. Our tool is used in our comprehensive cancer center and is made now publicly available for targeted therapy decisions.
In this report we describe a human pluripotent stem cell-derived vascular progenitor (MesoT) cell of the mesothelium lineage. MesoT cells are multipotent and generate smooth muscle cells, endothelial cells, and pericytes and self-assemble into vessel-like networks in vitro. MesoT cells transplanted into mechanically damaged neonatal mouse heart migrate into the injured tissue and contribute to nascent coronary vessels in the repair zone. When seeded onto decellularized vascular scaffolds, MesoT cells differentiate into the major vascular lineages and self-assemble into vasculature capable of supporting peripheral blood flow following transplantation. These findings demonstrate in vivo functionality and the potential utility of MesoT cells in vascular engineering applications.
Follistatin Effects in Migration, Vascularization, and Osteogenesis in vitro and Bone Repair in vivo
(2019)
The use of biomaterials and signaling molecules to induce bone formation is a promising approach in the field of bone tissue engineering. Follistatin (FST) is a glycoprotein able to bind irreversibly to activin A, a protein that has been reported to inhibit bone formation. We investigated the effect of FST in critical processes for bone repair, such as cell recruitment, osteogenesis and vascularization, and ultimately its use for bone tissue engineering. In vitro, FST promoted mesenchymal stem cell (MSC) and endothelial cell (EC) migration as well as essential steps in the formation and expansion of the vasculature such as EC tube-formation and sprouting. FST did not enhance osteogenic differentiation of MSCs, but increased committed osteoblast mineralization. In vivo, FST was loaded in an in situ gelling formulation made by alginate and recombinant collagen-based peptide microspheres and implanted in a rat calvarial defect model. Two FST variants (FST288 and FST315) with major differences in their affinity to cell-surface proteoglycans, which may influence their effect upon in vivo bone repair, were tested. In vitro, most of the loaded FST315 was released over 4 weeks, contrary to FST288, which was mostly retained in the biomaterial. However, none of the FST variants improved in vivo bone healing compared to control. These results demonstrate that FST enhances crucial processes needed for bone repair. Further studies need to investigate the optimal FST carrier for bone regeneration.
There is a great need for valuable ex vivo models that allow for assessment of cartilage repair strategies to reduce the high number of animal experiments. In this paper we present three studies with our novel ex vivo osteochondral culture platform. It consists of two separated media compartments for cartilage and bone, which better represents the in vivo situation and enables supply of factors pecific to the different needs of bone and cartilage. We investigated whether separation of the cartilage and bone compartments and/or culture media results in the maintenance of viability, structural and functional properties of cartilage tissue. Next, we valuated for how long we can preserve cartilage matrix stability of osteochondral explants during long-term culture over 84 days. Finally, we determined the optimal defect size that does not show spontaneous self-healing in this culture system. It was demonstrated that separated compartments for cartilage and bone in combination with tissue-specific medium allow for long-term culture of osteochondral explants while maintaining cartilage viability, atrix tissue content, structure and mechanical properties for at least 56 days. Furthermore, we could create critical size cartilage defects of different sizes in the model. The osteochondral model represents a valuable preclinical ex vivo tool for studying clinically relevant cartilage therapies, such as cartilage biomaterials, for their regenerative potential, for evaluation of drug and cell therapies, or to study mechanisms of cartilage regeneration. It will undoubtedly reduce the number of animals needed for in vivotesting.
Purpose
Hypertrophic cartilage is an important characteristic of osteoarthritis and can often be found in patients suffering from osteoarthritis. Although the exact pathomechanism remains poorly understood, hypertrophic de-differentiation of chondrocytes also poses a major challenge in the cell-based repair of hyaline cartilage using mesenchymal stromal cells (MSCs). While different members of the transforming growth factor beta (TGF-β) family have been shown to promote chondrogenesis in MSCs, the transition into a hypertrophic phenotype remains a problem. To further examine this topic we compared the effects of the transcription growth and differentiation factor 5 (GDF-5) and the mutant R57A on in vitro chondrogenesis in MSCs.
Methods
Bone marrow-derived MSCs (BMSCs) were placed in pellet culture and in-cubated in chondrogenic differentiation medium containing R57A, GDF-5 and TGF-ß1 for 21 days. Chondrogenesis was examined histologically, immunohistochemically, through biochemical assays and by RT-qPCR regarding the expression of chondrogenic marker genes.
Results
Treatment of BMSCs with R57A led to a dose dependent induction of chondrogenesis in BMSCs. Biochemical assays also showed an elevated glycosaminoglycan (GAG) content and expression of chondrogenic marker genes in corresponding pellets. While treatment with R57A led to superior chondrogenic differentiation compared to treatment with the GDF-5 wild type and similar levels compared to incubation with TGF-ß1, levels of chondrogenic hypertrophy were lower after induction with R57A and the GDF-5 wild type.
Conclusions
R57A is a stronger inducer of chondrogenesis in BMSCs than the GDF-5 wild type while leading to lower levels of chondrogenic hypertrophy in comparison with TGF-ß1.
Transmission of Trypanosoma brucei by tsetse flies involves the deposition of the cell cycle-arrested metacyclic life cycle stage into mammalian skin at the site of the fly’s bite. We introduce an advanced human skin equivalent and use tsetse flies to naturally infect the skin with trypanosomes. We detail the chronological order of the parasites’ development in the skin by single-cell RNA sequencing and find a rapid activation of metacyclic trypanosomes and differentiation to proliferative parasites. Here we show that after the establishment of a proliferative population, the parasites enter a reversible quiescent state characterized by slow replication and a strongly reduced metabolism. We term these quiescent trypanosomes skin tissue forms, a parasite population that may play an important role in maintaining the infection over long time periods and in asymptomatic infected individuals.
Salivary gland tumors (SGTs) are a relevant, highly diverse subgroup of head and neck tumors whose entity determination can be difficult. Confocal Raman imaging in combination with multivariate data analysis may possibly support their correct classification. For the analysis of the translational potential of Raman imaging in SGT determination, a multi-stage evaluation process is necessary. By measuring a sample set of Warthin tumor, pleomorphic adenoma and non-tumor salivary gland tissue, Raman data were obtained and a thorough Raman band analysis was performed. This evaluation revealed highly overlapping Raman patterns with only minor spectral differences. Consequently, a principal component analysis (PCA) was calculated and further combined with a discriminant analysis (DA) to enable the best possible distinction. The PCA-DA model was characterized by accuracy, sensitivity, selectivity and precision values above 90% and validated by predicting model-unknown Raman spectra, of which 93% were classified correctly. Thus, we state our PCA-DA to be suitable for parotid tumor and non-salivary salivary gland tissue discrimination and prediction. For evaluation of the translational potential, further validation steps are necessary.
Addition of heparin binding sites strongly increases the bone forming capabilities of BMP9 in vivo
(2023)
Highlights
• Despite not being crucial for bone development BMP9 can induce bone growth in vivo.
• BMP9 induced bone formation is strongly enhanced by introduced heparin binding sites.
• BMP9s bone forming capabilities are triggered by extracellular matrix binding.
• Heparin binding BMP9 (BMP9 HB) can improve the current therapies in treating bone fractures.
Abstract
Bone Morphogenetic proteins (BMPs) like BMP2 and BMP7 have shown great potential in the treatment of severe bone defects. In recent in vitro studies, BMP9 revealed the highest osteogenic potential compared to other BMPs, possibly due to its unique signaling pathways that differs from other osteogenic BMPs. However, in vivo the bone forming capacity of BMP9-adsorbed scaffolds is not superior to BMP2 or BMP7. In silico analysis of the BMP9 protein sequence revealed that BMP9, in contrast to other osteogenic BMPs such as BMP2, completely lacks so-called heparin binding motifs that enable extracellular matrix (ECM) interactions which in general might be essential for the BMPs' osteogenic function. Therefore, we genetically engineered a new BMP9 variant by adding BMP2-derived heparin binding motifs to the N-terminal segment of BMP9′s mature part. The resulting protein (BMP9 HB) showed higher heparin binding affinity than BMP2, similar osteogenic activity in vitro and comparable binding affinities to BMPR-II and ALK1 compared to BMP9. However, remarkable differences were observed when BMP9 HB was adsorbed to collagen scaffolds and implanted subcutaneously in the dorsum of rats, showing a consistent and significant increase in bone volume and density compared to BMP2 and BMP9. Even at 10-fold lower BMP9 HB doses bone tissue formation was observed. This innovative approach of significantly enhancing the osteogenic properties of BMP9 simply by addition of ECM binding motifs, could constitute a valuable replacement to the commonly used BMPs. The possibility to use lower protein doses demonstrates BMP9 HB's high translational potential.